Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar-Apr;33(2):507-514.
doi: 10.21873/invivo.11503.

Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases

Yumiko Akano #  1 , Kozo Kuribayashi #  2   3 , Norihiko Funaguchi  4 , Yuichi Koda  1 , Eriko Fujimoto  1 , Koji Mikami  1 , Toshiyuki Minami  1 , Ryo Takahashi  1 , Takashi Yokoi  1   3 , Takashi Kijima  1   3
Affiliations

Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases

Yumiko Akano et al. In Vivo. 2019 Mar-Apr.

Abstract

Background/aim: Nivolumab is an immune checkpoint inhibitor for advanced non-small cell lung cancer (NSCLC). We investigated the safety and efficacy of nivolumab by analyzing the response factor, adverse effects (AE), and the post-treatment condition of pretreated advanced or recurrent NSCLC patients.

Patients and methods: Nivolumab (3 mg/kg) was administered to 79 pre-treated NSCLC patients from December 2015 to January 2018. Nivolumab efficacy and AE were assessed using the Response Evaluation Criteria in Solid Tumors and the Common Terminology Criteria, respectively.

Results: Progression-free survival (PFS) was significantly prolonged in cases where the therapeutic effect of the pretreatment was a partial response (p=0.0004). Five cases (6.3%) experienced grade 3-4 AEs. PFS was significantly prolonged in the skin rash group versus the non-skin rash group, and in patients where nivolumab treatment was discontinued.

Conclusions: Long-term survival was observed in patients with skin rash. Therapeutic effect of nivolumab immediately following its administration appears to be favorable for survival.

Keywords: Immune checkpoint inhibitor; durable response; immune-related adverse event; nivolumab; non-small cell lung cancer; programmed cell death ligand 1.

PubMed Disclaimer

Conflict of interest statement

The Authors have no conflicts of interest to declare regarding the contents of this article.

Figures

Figure 1
Figure 1. Kaplan–Meier curve for median progression-free survival (PFS) and overall survival (OS) across all cases.
Figure 2
Figure 2. Kaplan-Meier curve for median progression-free survival period with respect to age (a), sex (b), histological classification (c), and epidermal growth factor receptor mutation and wild-type (WT) strain (d).
Figure 3
Figure 3. Comparison of progression-free survival (PFS) between non-smokers and smokers (a). Comparison of PFS for patients with a performance status (PS) score of 0-1 and 2 (b).
Figure 4
Figure 4. Comparison of progression-free survival (PFS) (a) and overall survival (OS) periods (b) between patients with and without skin rash.
Figure 5
Figure 5. Comparison of progression-free survival (a) and overall survival periods (b) between groups discontinued from nivolumab due to adverse events and progressive disease.
Figure 6
Figure 6. Kaplan–Meier curve for progression-free survival periods of pre-treated patients before Nivolumab. Partial response (PR), stable disease (SD), and progressive disease (PD).
See this image and copyright information in PMC

References

    1. Suzuki S, Ishida T, Yoshikawa K, Ueda R. Current status of immunotherapy. Japanese J Clin Oncol. 2016;46(3):191–203. - PubMed
    1. Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, Singh S, Wong S, Garner N, Leblanc H, Bunch RT, Blanset D, Selby MJ, Korman AJ. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;9:846–856. - PubMed
    1. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 5 2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504–535. - PubMed
    1. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med. 2017;376(25):2415–2426. - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt W, Poddubskaya E, Antonia S, Pluzanski A, Vokes E, Holgado E, Waterhouse D, Ready N, Gaino J, Fontera OA, Havel L, Steins M, Grassino M, Aerts J, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;9:123–135. - PMC - PubMed

MeSH terms

LinkOut - more resources